Tipranavir
Cardiovascular Disease
Kirby InstituteSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
60 Active assets in the Cardiovascular Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid AstraZeneca | Phase 4 | BBB |
Liraglutide University of Sao Paulo General Hospital | Phase 4 | BBB |
Lipitor Duke University | Phase 4 | BBB |
Rosuvastatin Nanjing First Hospital, Nanjing Medical University | Phase 4 | BBB |
SIMVASTATIN McMaster University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Tipranavir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →